Microbiota-targeted therapies in inflammation resolution. (January 2022)

• Record Type: Journal Article
• Authors: Strati, Francesco; Lattanzi, Georgia; Amoroso, Chiara; Facciotti, Federica
• Is Part Of: Seminars in immunology. Volume 59(2022)
• Publication Date: 2022-01
• Subjects: AAD Antibiotic-associated diarrhea -- AIDS Acquired Immune Deficiency Syndrome -- AD Alzheimer Disease -- AMPs Antimicrobial Peptides -- ART Antiretroviral Therapy -- BSI Bloodstream Infections -- CAD Coronary artery disease -- CD Crohn's Disease -- CDI C. Difficile Infection -- CHF Chronic heart failure -- CNS Central Nervous System -- CTLA Cytotoxic T Lymphocyte-Associated Antigen -- CVD Cardiovascular disease -- DSS Dextran Sodium Sulfate -- EAM experimental autoimmune myocarditis -- EAE Experimental Autoimmune Encephalomyelitis -- HF Heart failure -- FMT Fecal Microbiota Transplantation -- FOS Fructo-Oligosaccharides -- GF Germ-Free -- GI Gastrointestinal -- GMM Genetically Modified Microorganisms -- GVHD Graft versus Host Disease -- HIV Human Immunodeficiency Virus -- HSCT Hematopoietic Stem Cell Transplantation -- IFN Interferon -- IL Interleukin -- iNKT Invariant Natural Killet T Cells -- IPA Indole Propionic Acid -- LBPs Live Biotherapeutics Products -- LPS Lipopopolysaccharide -- mLNs Mesenteric Lymph Nodes -- MS Multiple Sclerosis -- NF-Kb Nuclear Factor Kappa Light Chain Enhancer Of Activated B Cells -- PD Parkinson's Disease -- PD-1 Programmed Cell Death Protein 1 -- PD-L1 Programmed Cell Death Ligand 1 -- PSA Polysaccharide A -- PT Phage Therapy -- QS Quorum Sensing -- RCTs Randomized Clinical Trials -- rCDI Recurrent CDI -- SCFA Short-Chain Fatty Acids -- T1D Type1 Diabetes -- TB Tuberculosis -- TLR Toll-Like Receptor -- Th T-Helper -- TMAO trimethylamine-N-oxide TNF Tumor Necrosis Factor -- Tregs Regulatory T Cells -- RA Rheumatoid Arthritis -- UC Ulcerative Colitis; Gut microbiome -- Inflammation -- Probiotics -- FMT -- Mucosal immunity -- Live biotherapeutic products; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Immunity -- Periodicals; Immunologie -- Périodiques; Electronic journals; 616.079
• DOI: 10.1016/j.smim.2022.101599
• Languages: English
• ISSNs: 1044-5323

Abstract

Graphical abstract: Highlights: The gut microbiota regulates the susceptibility to intestinal and extra intestinal diseases modulating host immunity and inflammation. Manipulation of the microbiota improve inflammation and disease outcome. The translational value of the microbiota is demonstrated by the efficacy of new microbiota-targeted therapies. Abstract: Gut microbiota has been shown to systemically shape the immunological landscape, modulate homeostasis and play a role in both health and disease. Dysbiosis of gut microbiota promotes inflammation and contributes to the pathogenesis of several major disorders in gastrointestinal tract, metabolic, neurological and respiratory diseases. Much effort is now focused on understanding host-microbes interactions and new microbiota-targeted therapies are deeply investigated as a means to restore health or prevent disease. This review details the immunoregulatory role of the gut microbiota in health and disease and discusses the most recent strategies in manipulating individual patient's microbiota for the management and prevention of inflammatory conditions.